市場調查報告書
商品編碼
1197327
顱內支架市場 - 增長、趨勢和預測 (2023-2028)Intracranial Stents Market - Growth, Trends, and Forecasts (2023 - 2028) |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
在預測期內,顱內支架市場預計將以 7.59% 的複合年增長率註冊。
COVID-19 大流行影響了顱內支架市場的增長。 由於 COVID-19 相關措施導致擇期手術延遲對顱內支架市場產生了負面影響,尤其是在 2020 年,由於資源轉移給 COVID-19 患者,大多數手術被取消或推遲。。 世界範圍內的外科手術顯著減少。 例如,英國外科雜誌報導稱,2020 年 5 月,印度每週取消約 48,728 台手術,估計 12 週內取消了 585,000 台。 然而,隨著 COVID-19 限制措施的解除、手術的重新開放以及因事故導致的就診和住院人數增加,所研究的市場有望在未來 2-3 年內從 COVID-19 的下滑中恢復過來。
中風患病率上升、對微創顱內手術的需求增加以及老年人口增加等因素正在推動市場增長。 例如,根據世界中風組織 2022 年的報告,全球每年報告的新中風病例超過 1220 萬例。 根據同一數據,中風患病率在 70 歲及以上人群中最高 (67%),其次是 15-49 歲人群 (22%)。 因此,中風的高負擔,加上老年人口的增加,預計會增加對支架取栓治療的需求,以去除形成大腦的血栓。 預計這將在預測期內刺激市場增長。
此外,根據 2022 年 10 月在埃及神經病學、精神病學和神經外科雜誌上發表的一篇文章,顱內動脈粥樣硬化性狹窄 (ICAS) 是全球中風的主要原因之一,患病率因人口統計而異,據說是亞裔、西班牙裔和美國人。 根據同一來源,ICAS 佔每年發生的大約 900,000 例中風和短暫性腦缺血發作 (TIA) 的 10%,這些患者每年有 15% 的複發機會。我在這裡。 此外,在亞洲國家,歸因於 ICAS 的卒中比例 (33-50%) 高於美國和西方國家 (10-15%)。 因此,由於 ICAS 的負擔更大,預計亞洲國家的人們患中風的風險更高。 預計這將增加對顱內支架置入術的需求,推動市場增長。
此外,越來越多的公司和大學開發技術先進的支架也促進了市場增長。 例如,2022 年 1 月,MicroPort NeuroTech Limited 在 PROMISE 研究中招募了第一名患者,這是一項評估顱內動脈瘤治療的 Rebridge 顱內可視化支架上市前臨床試驗。 在此背景下,市場有望在預測期內擴大。 然而,缺乏熟練的專業人員使用顱內支架和顱內支架的腦血管並發症可能會阻礙預測期內顱內支架市場的增長。
預計在預測期內,腦動脈瘤部分的顱內支架市場將出現顯著增長。 該領域增長的驅動因素是腦動脈瘤發病率上升以及患這種疾病的高危老年人口不斷增加。
人口老齡化更容易患腦動脈瘤,這有望刺激市場增長。 例如,2021 年 10 月發表在 Annals of Medicine 上的一篇論文觀察到,未破裂腦動脈瘤的發生率在 60 歲以上的患者中最高。 此外,2021 年 9 月發表在 NLM 上的一篇論文證實,未破裂的動脈瘤在老年女性中很常見,在 60 至 69 歲的日本女性中患病率最高為 14.5%。。 根據世界衛生組織公佈的數據,到2022年10月,到2021年全球約有10億人將達到或超過65歲。 此外,預計到 2030 年將增加到 14 億。 這樣,隨著老年人口的增加,腦動脈瘤在人群中的負擔較大,因此預計腦部手術清除血栓的需求會增加。 預計這將推動市場增長。
此外,大腦和神經系統疾病領域研發活動的增加、大腦相關治療方式的增加以及產品發布和批准的增加也將在預測期內加速市場增長。 例如,2022年2月,微創神經科技有限公司自主研發的Neurohawk支架取栓器獲得中國國家藥品監督管理局(NMPA)的上市許可。 該裝置是一種自膨脹式血栓支架取栓器,用於血管內有創血栓切除術,用於清除血管內的大血栓。 因此,由於上述因素(例如腦動脈瘤和相關風險因素的增加以及產品批准的增加),預計研究部門在預測期內將顯著增長。
由於人口中顱內狹窄和腦動脈瘤的發病率上升以及發達的醫療保健系統的存在等因素,預計在預測期內北美的顱內支架市場將增長。預計將佔據主導地位。 此外,對微創手術的需求不斷增加以及技術先進的顱內支架的不斷增加預計將推動該地區的市場增長。
神經系統疾病、特發性顱內高壓和腦動脈瘤患病率上升是推動市場增長的關鍵因素。 例如,根據腦動脈瘤基金會公佈的2022年數據,美國每年約有650萬人患有未破裂的腦動脈瘤。 年破裂率約為每 10 萬人 8-10 例。 根據同一數據,美國每年約有 30,000 人患有腦動脈瘤破裂。 因此,預計患有腦動脈瘤的人數眾多將增加對顱內支架的需求並推動市場增長。
此外,根據 2022 年 5 月發表的一篇論文,顱內主動脈瓣狹窄 (ILAS) 是美國缺血性中風的重要原因。 因此,該國中風相關疾病的負擔越來越重,預計這將推動該國對用於中風相關手術的顱內支架的需求。
此外,採用籌款和合作夥伴關係等各種業務戰略的公司越來越多,預計也將推動市場增長。 例如,2021 年 8 月,Fluid Biotech 在種子輪融資中籌集了 470 萬美元。 合同製造商將使用這筆資金來計劃生產啟動、監管裡程碑的完成,以及用於治療腦動脈瘤的革命性支架(聚合物金屬混合流體轉向腦支架)的首次人體植入。用於參與 因此,由於上述因素,預計市場在預測期內將顯著增長。
這個市場競爭激烈,世界上主要的公司製造了大部分顱內支架。 擁有更多研究資金和更好的分銷系統的市場領導者正在市場中站穩腳跟。 此外,隨著亞太地區獲得認可,小型企業也出現了。 這也推動了市場的增長。 市場參與者包括 Penumbra, Inc、Medtronic Plc、Stryker Corporation、Boston Scientific Corporation、Johnson & Johnson Services, Inc、Terumo Corporation、Cook Group、MicroPort Scientific 和 Acandis GmbH。
The intracranial stents market is expected to register a CAGR of 7.59% over the forecast period.
The COVID-19 pandemic has impacted the growth of the intracranial stents market. The delays in performing elective procedures due to COVID-19-related measures had adversely affected the intracranial stents market, especially in 2020, as most of the procedures were canceled or postponed due to the diversion of resources toward the COVID-19 patients. There was a significant decrease in surgical procedures worldwide. For instance, according to the report of the British Journal of Surgery, in May 2020, around 48,728 surgical procedures per week were canceled in India which is estimated around 585,000 surgical procedures for 12 weeks. However, with the released COVID-19 restrictions, resumed surgical procedures and increased hospital visits and admissions due to accidents, the studied market is expected to recover from the decline of COVID-19 in the next two-three years.
Factors such as the rising prevalence of stroke, increasing demand for minimally invasive intracranial surgeries, and the growing geriatric population are boosting the market growth. For instance, as per the World Stroke Organization report of 2022, more than 12.2 million new stroke cases are reported each year, globally. In addition, as per the same source, the prevalence of stroke is highest among people aged 70 years and above (67%), followed by people aged between 15-49 years (22%). Thus, the high burden of stroke coupled with the increasing geriatric population is expected to increase the demand for stent-retriever thrombectomy treatment for removing blood clots forming the brain. This is anticipated to fuel the market growth over the forecast period.
Additionally, as per an article published in the Egyptian Journal of Neurology, Psychiatry, and Neurosurgery, in October 2022, intracranial atherosclerotic stenosis (ICAS) is one of the main causes of stroke worldwide and its prevalence varies depending on the demographic, with Asians, Hispanics,n Americans. In addition, as per the same source, ICAS affects 10% of the estimated 900,000 strokes or transient ischemic episodes (TIAs) yearly, and the probability of recurrence in these patients is 15% annually. Also, the Asian populations have a greater rate of strokes (33-50%) that can be attributed to ICAS as compared to the United States and western nations (10-15%). Thus, the high burden of ICAS among the population is expected to increase their risk of experiencing a stroke. This in turn is anticipated to fuel the demand for intracranial stenting procedures, hence propelling the market growth.
Furthermore, the rising company and university activities in developing technologically advanced stents are also contributing to the market growth. For instance, in January 2022, MicroPort NeuroTech Limited enrolled the first patient in the PROMISE Study, a pre-market clinical study for the Rebridge Intracranial Visualized Stent evaluating the treatment of an intracranial aneurysm. Therefore, owing to the aforementioned factors the studied market is expected to grow over the forecast period. However, the lack of skilled professionals for operating using intracranial stents and cerebrovascular complications related to intracranial stenting are likely to impede the growth of the intracranial stent market over the forecast period.
The brain aneurysm segment is expected to witness significant growth in the intracranial stenting market over the forecast period. The factors attributing to the segment growth are the rising incidence of brain aneurysms and the increasing geriatric population who are at greater risk of having this disease.
The increasing geriatric population is more prone to develop brain aneurysms which are anticipated to fuel the market growth. For instance, as per an article published in the Annals of Medicine, in October 2021, it has been observed that the incidence of unruptured cerebral aneurysms is highest in patients over 60 years. Also, from an article published in NLM, in September 2021, it has been observed that unruptured aneurysms were more common in elderly women with a peak prevalence of 14.5% in Japanese women aged between 60-69 years. Also, according to the data published by WHO, in October 2022, about 1 billion people living globally were aged 65 years or above, in 2021. In addition, this number is projected to increase to 1.4 billion by 2030. Thus, the high burden of brain aneurysms among the population along with the growing elderly population is expected to raise the need for brain surgeries to remove blood clots. This is anticipated to propel the market growth.
Moreover, growing research and development activities in the field of brain and neurological disorders and the increasing number of therapeutic procedures associated with the brain as well as rising product launches and approvals are also expected to implicitly accelerate the growth of the market during the forecast period. For instance, in February 2022, MicroPort NeuroTech Limited received marketing approval from China's National Medical Products Administration (NMPA) for its self-developed Neurohawk Stent Thrombectomy Device. The device is a self-expandable clot stent retriever used in endovascular invasive thrombectomy procedures to remove large clots in blood vessels. Thus, owing to the aforementioned factors such as the rising burden of brain aneurysms and associated risk factors as well as increasing product approvals, the studied segment is expected to grow significantly during the forecast period.
North America is expected to dominate the intracranial stent market over the forecast period owing to the factors such as the rising incidences of intracranial stenosis and brain aneurysms among the population, and the presence of a well-structured healthcare system. Also, the increasing demand for minimally invasive procedures as well as growing technologically advanced intracranial stents is expected to increase the market growth in the region.
The growing prevalence of neurological disorders, idiopathic intracranial hypertension, and brain aneurysm is the key factor driving the market growth. For instance, according to 2022 data published by the Brain Aneurysm Foundation, about 6.5 million people in the United States have an unruptured brain aneurysm, annually. The annual rate of rupture is approximately about 8 - 10 per 100,000 people. According to the same source, about 30,000 people in the United States suffer a brain aneurysm rupture each year. Thus, the high number of people suffering from brain aneurysms is expected to increase the demand for intracranial stents hence boosting the market growth.
Additionally, as per the article published in May 2022, intracranial large artery stenosis (ILAS) is an important contributor to ischemic stroke in the United States. Thus, the burden of diseases related to stroke is increasing in the country and this is expected to drive the demand for intracranial stents used for stroke-related surgeries in the country.
Furthermore, the rising company focus on adopting various business strategies such as financing, collaborations, and others are also expected to increase the market growth. For instance, in August 2021, Fluid Biotech raised USD 4.7 million in the seed funding round. This fund is used to engage contract manufacturers to initiate production, complete regulatory milestones, and plan for the first-in-human implantation of its innovative stent, a hybrid polymer-metal flow-diverting brain stent, for treating brain aneurysms. Thus, owing to the aforementioned factors, the studied market is expected to grow significantly during the forecast period.
The market is fairly competitive with the presence of global key players manufacturing the majority of intracranial stents. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow. Some of the key companies in the market are Penumbra, Inc., Medtronic Plc, Stryker Corporation, Boston Scientific Corporation, Johnson & Johnson Services, Inc., Terumo Corporation, Cook Group, MicroPort Scientific and Acandis GmbH among others.